{"entity":{"id":"nct06896890","kind":"trial","name":"Cisplatin (CIS) Administered As Dry Powder for Inhalation (DPI) in Patients with Stage IV Non-Small Cell Lung Cancer","aka":[],"tldr":"A phase 1/2 trial of CIS-DPI in non-small-cell lung cancer, run by Inhatarget Therapeutics, now recruiting.","summary":"Cisplatin (CIS) Administered As Dry Powder for Inhalation (DPI) in Patients with Stage IV Non-Small Cell Lung Cancer is a phase 1/2 interventional study registered as NCT06896890 by Inhatarget Therapeutics, with 32 participants planned, started 2023-06-23 and due to reach its primary completion in 2026-10-01. Interventions recorded: CIS-DPI.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06896890","url":"https://clinicaltrials.gov/study/NCT06896890"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["nsclc"],"sections":[],"technologies":["cytotoxic-chemotherapy","platinum"],"targets":[],"drugs":["cisplatin"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT06896890","phase":"1/2","setting":"A Phase I/II First-in-human Trial Investigating Safety, Tolerability, Pharmacokinetics and Anti-tumour Activity of Ascending Doses of a Dry Powder Cisplatin Formulation for Inhalation to Treat Stage IV Non-small Cell Lung Cancer Patients","sponsor":"Inhatarget Therapeutics","started":"2023-06-23","startedType":"actual","enrolled":32,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct06896890/","neighbours":{"cancer":[{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"}],"technology":[{"id":"cytotoxic-chemotherapy","kind":"technology","name":"Cytotoxic chemotherapy","route":"/technologies/cytotoxic-chemotherapy/"},{"id":"platinum","kind":"technology","name":"Platinum agents","route":"/technologies/platinum/"}],"drug":[{"id":"cisplatin","kind":"drug","name":"Cisplatin","route":"/drugs/cisplatin/"}]}}